Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45228 | 0.82 | LMNA (0.50) | ADRA1DHPGDCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2886837 | 0.81 | TAAR1 (0.52) | CYP17A1CYP11B1CYP11B2ADRA1DCYP3A4 | |
| SCHEMBL8306418 | 0.80 | ADRA1D (0.49) | ADRA1DCYP3A4CYP1A2CYP2D6CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL27757668 | 0.80 | LMNA (0.49) | ADRA1DHPGDCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9825918 | 0.80 | LMNA (0.49) | ADRA1DHPGDCYP2C9CYP2C19ALDH1A1 | |
| Methane SCHEMBL11161392 | 0.80 | LMNA (0.49) | ADRA1DHPGDCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL24769737 | 0.79 | ADRA1D (0.51) | CYP17A1CYP11B1CYP11B2ADRA1DCYP3A4 | |
| SCHEMBL559559 | 0.78 | TAAR1 (0.56) | ADRA1DHPGDCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2882542 | 0.78 | TAAR1 (0.53) | CYP17A1CYP11B1CYP11B2TAAR1ADRA2A | |
| SCHEMBL2885846 | 0.78 | TAAR1 (0.53) | CYP17A1CYP11B1CYP11B2TAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081859-A1 | TRIAZINE AMINO DERIVATIVES FOR TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3004099-B1 | TETRAHYDROPYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-04-19 | — | — | EP | disclosed |
| CN-103709096-B | Urea type derivative used as nicotinamide ribose phosphate transferase inhibitor, as well as preparation method and application thereof | 中国人民解放军第二军医大学 | 2017-01-18 | — | — | CN | disclosed |
| EP-3004099-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9062075-B2 | Tetrahydropyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| WO-2014195844-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| CN-103709096-A | Urea type derivative used as nicotinamide ribose phosphate transferase inhibitor, as well as preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2014-04-09 | — | — | CN | disclosed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| US-4866180-A | MITOMYCIN ANALOGS; ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | F12, FAR1, NQO2 | CYP17A1 2696/4885CYP11B1 2074/4885CYP11B2 2453/4885 |
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CYP17A1 939/4885CYP11B1 155/4885CYP11B2 219/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CYP17A1 939/4885CYP11B1 155/4885CYP11B2 219/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CYP17A1 939/4885CYP11B1 155/4885CYP11B2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.